TRDA
Entrada Therapeutics, Inc. · Healthcare · Market cap $267.9M
Insiders sold $10.3M net in the last 90 days ·4 sellers, 0 buyers· latest Form 4 filed Sep 9, 2026
Insider Buying
$1.6M
reported purchases (SEC code P)
Insider Selling
$15.1M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Sep 9, 2026
MPM BIOVENTURES 2018, L.P.
Entrada Therapeutics, Inc. (TRDA) has 32 SEC Form 4 filings (78 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Sep 9, 2026.
Inside the rolling window, 9 insiders at Entrada Therapeutics, Inc. reported 5 open-market purchases totaling $1.6M and 44 open-market sales totaling $15.1M. The most active filer is 10% Owner MPM BIOVENTURES 2018, L.P. with 12 filings. Insiders have net sold $11.0M over the trailing 6 months. The most recent open-market filing is a sale of 38,500 shares by 10% Owner MPM BIOVENTURES 2018, L.P., dated Sep 4, 2026, worth $274K.
- Industry:Biotechnology
- CEO:Dipal Doshi
- Employees:152
- HQ:Boston, MA, US
- IPO:2021-10-29
| Source | |||||||
|---|---|---|---|---|---|---|---|
| 10% Owner | Sale | 38,500 | $274K | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 192,500 | $1.4M | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 28,837 | $206K | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 38,500 | $274K | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 192,500 | $1.4M | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 28,837 | $206K | Sep 9 | -3.2% | SEC ↗ | |
| 10% Owner | Sale | 29,088 | $205K | Sep 3 | -4.0% | SEC ↗ | |
| 10% Owner | Sale | 25,131 | $181K | Sep 3 | -4.0% | SEC ↗ | |
| 10% Owner | Sale | 32,263 | $231K | Sep 3 | -4.0% | SEC ↗ | |
| 10% Owner | Sale | 29,088 | $205K | Sep 3 | -4.0% | SEC ↗ | |
| 10% Owner | Sale | 25,131 | $181K | Sep 3 | — | SEC ↗ | |
| 10% Owner | Sale | 32,263 | $231K | Sep 3 | — | SEC ↗ | |
| 10% Owner | Sale | 38,922 | $280K | Aug 31 | — | SEC ↗ | |
| 10% Owner | Sale | 3,733 | $26K | Aug 31 | — | SEC ↗ | |
| 10% Owner | Sale | 44,259 | $309K | Aug 31 | — | SEC ↗ | |
| 10% Owner | Sale | 38,922 | $280K | Aug 31 | — | SEC ↗ | |
| 10% Owner | Sale | 3,733 | $26K | Aug 31 | — | SEC ↗ | |
| 10% Owner | Sale | 44,259 | $309K | Aug 31 | — | SEC ↗ | |
MPM BioVentures 2014, L.P.First in 9 months | 10% Owner | Sale | 21,623 | $159K | Aug 27 | — | SEC ↗ |
MPM BioVentures 2014, L.P.First in 9 months | 10% Owner | Sale | 26,522 | $200K | Aug 27 | — | SEC ↗ |
MPM BioVentures 2014, L.P.First in 9 months | 10% Owner | Sale | 14,569 | $103K | Aug 27 | — | SEC ↗ |
MPM BIOVENTURES 2018, L.P.First in 8 months | 10% Owner | Sale | 21,623 | $159K | Aug 27 | — | SEC ↗ |
MPM BIOVENTURES 2018, L.P.First in 8 months | 10% Owner | Sale | 26,522 | $200K | Aug 27 | — | SEC ↗ |
MPM BIOVENTURES 2018, L.P.First in 8 months | 10% Owner | Sale | 14,569 | $103K | Aug 27 | — | SEC ↗ |
| Director | Sale | 10,494 | $73K | Aug 10 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does TRDA have?
Entrada Therapeutics, Inc. (TRDA) has 32 SEC Form 4 filings (78 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Sep 9, 2026.
When was the most recent SEC Form 4 filing for TRDA?
The most recent Form 4 filing for TRDA on Tracefour is dated Sep 9, 2026.
Who is the most active insider at TRDA?
The most active SEC Form 4 filer at TRDA in the rolling window is 10% Owner MPM BIOVENTURES 2018, L.P., with 12 filings.
What is the net insider flow at TRDA over the last 6 months?
Over the trailing 180 days, insiders at TRDA have net sold $11.0M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at TRDA in the current window?
Inside the rolling window, insiders at TRDA bought $1.6M and sold $15.1M based on SEC Form 4 filings.
Can I get alerts for TRDA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Entrada Therapeutics, Inc. (TRDA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Entrada Therapeutics, Inc. is in the Healthcare sector.